RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

▴ RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms

RedHill Biopharma Ltd., a speciality biopharmaceutical company, recently announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva, ABC294640) in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.

The randomized, double-blind, placebo-controlled U.S. Phase 2 proof-of-concept study with opaganib enrolled 40 patients requiring oxygen support. The study was not powered for statistical significance and aimed to evaluate the safety and identify preliminary signs of activity. Patients in the study were randomized at a 1:1 ratio to receive either opaganib or placebo on top of standard-of-care (SoC) and were followed up for up to 42 days of post-treatment initiation.

Top-line results from the study found opaganib to be safe, with no material safety differences between the opaganib and placebo treatment arms. Overall, fewer patients suffered from serious adverse events (SAEs) in the opaganib treatment arm than in the placebo arm. In this small sample size, there were few events of intubation or fatality and these were balanced between the two arms.
The opaganib-treated arm demonstrated a consistent trend of greater improvement in reducing oxygen requirement by end of treatment on Day 14 across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization ordinal scale:
- A greater improvement in the proportion of patients reaching room air and no longer requiring oxygen support by Day 14 vs. the control arm (52.6% vs. 22.2%).
- A greater improvement in the proportion of patients with 50% reduction in supplemental oxygen by day 14 vs. the control arm (89.5% vs. 66.7%).
- A higher proportion of patients discharged by Day 14 vs. the control arm (73.7% vs. 55.6%).
- A greater reduction from baseline of the median total oxygen requirement (AUC) over 14 days vs. the control arm (68.0% vs. 46.7%).
Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks. The Company will provide the data for peer review when available.

"We are pleased with these encouraging top-line results from our exploratory Phase 2 study which confirm opaganib's safety and demonstrate promising signals of activity when treating patients with COVID-19 and who require oxygen support. These preliminary results support our ongoing global Phase 2/3 study in severe COVID-19 pneumonia, which is expected to read out in Q1/2021. We continue to work diligently to compile a robust data set to support potential filing of global emergency use applications," said Mark L. Levitt, MD, PhD., Medical Director at RedHill.

Gilead Raday, RedHill's Chief Operating Officer, added: "Opaganib has a unique dual mode of action that is both anti-inflammatory and antiviral – acting on both the cause and the effects of COVID-19. Opaganib targets sphingosine kinase-2, a human cell component involved in viral replication and not the virus itself. The mounting evidence of new SARS-CoV-2 mutations emerging globally underscores the importance of this unique mechanism, which potentially minimizes the risk of viral resistance to therapy. The trends of patient improvement shown by the preliminary top-line data support the ongoing Phase 2/3 study with opaganib, which will provide a more in-depth understanding of opaganib's activity."

The efficacy of opaganib in severe COVID-19 pneumonia is being further explored in an ongoing global Phase 2/3 study and is expected to report top-line data in the first quarter of 2021. This study is being conducted across approximately 30 clinical sites in several countries and is on track to enroll up to 270 patients. The study has undergone two unblinded reviews of safety data by an independent Data and Safety Monitoring Board (DSMB), with unanimous recommendations to continue the study. An interim DSMB futility analysis will be conducted in the coming weeks, evaluating data from the first 135 subjects that have reached the primary endpoint.

The top-line results from the U.S. Phase 2 study of opaganib in patients hospitalized with COVID-19 pneumonia are preliminary and were provided to the Company by an independent third-party following an initial independent analysis and remain subject to additional review and analysis. Such review and analysis may result in findings inconsistent with the results disclosed in this release and may not be replicated in future studies.

Tags : #RedHillBiopharma #LatestNewsonRedHillBiopharma2ndJan #LatestPharnaNews2ndJan #COVID-19Pneumonia #LatestNewsonCOVIDTreatment #WHO

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Our Brain's Hunger Games: How Mental Cravings Attack ImmunityApril 09, 2025
Inhale Anxiety, Exhale Joy: Is Air Pollution Ruining Mental Health?April 09, 2025
Are You Slowly Killing Your Brain: Habits That Steal Your Memory, Mood, and Mental StrengthApril 09, 2025
Baby & Mom Retail Launches it's New Healthcare Equipment Brand CORVELLApril 09, 2025
Wellbeing Nutrition unveils a new campaign with their Brand Ambassador, Sharvari, Celebrating the power of “Beauty Within”April 09, 2025
Given the rise in heart attack cases in womenApril 08, 2025
CARE Hospitals Marks World Health Day 2025 with ‘Walk for a Healthy Beginning’ at CharminarApril 08, 2025
Cancer, Obesity, Mental Health, India’s top health concerns: Ipsos Health Service Report 2024 April 08, 2025
Why Loneliness Might Be the Real Reason You're Always Falling SickApril 08, 2025
Is Your Beverage Choice Secretly Harming Your Mind?April 08, 2025
India’s Hidden Health Pandemic: Vitamin D Deficiency Affects One in FiveApril 08, 2025
Xavier University strengthens ties with India through strategic visitApril 08, 2025
Desire, Distraction, and Distress: The Untold Connection of ADHD and SexApril 08, 2025
Medical breakthrough unlocks rare disease discoveryApril 08, 2025
Elevate your space with the Crompton’s 3-star energy efficient, Avancer Swirl Ceiling Fan – a perfect combination of Aesthetics and Technology!April 07, 2025
CARE Hospitals Launches ‘SANGHAM’ Card on World Health DayApril 07, 2025
Sharda Care Healthcity partners with Prometheus School to strengthen awareness on healthy living among communities this World Health DayApril 07, 2025
Sharda Care Healthcity partners with Prometheus School to strengthen awareness on healthy living among communities this World Health DayApril 07, 2025
When the Fight Comes Back: Tahira’s Relapse and the Reality of Breast Cancer Beyond RecoveryApril 07, 2025
Beyond Hospitals and Hashtags: What World Health Day Should Really Teach UsApril 07, 2025